Mycosis fungoides

Common Name(s)

Mycosis fungoides

Mycosis fungoides is a disease in which T-cell lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. The rash may last for months or years without causing any symptoms. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. Finally, tumors form which may develop into ulcers and become infected. Mycosis fungoides is difficult to cure. Treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Mycosis fungoides" for support, advocacy or research.

Cutaneous Lymphoma Foundation

The Cutaneous Lymphoma Foundation is an independent, nonprofit patient advocacy organization whose mission is supporting every person with cutaneous lymphoma by promoting awareness and education, advancing patient care and facilitating research.

Last Updated: 6 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Mycosis fungoides" for support, advocacy or research.

Cutaneous Lymphoma Foundation

The Cutaneous Lymphoma Foundation is an independent, nonprofit patient advocacy organization whose mission is supporting every person with cutaneous lymphoma by promoting awareness and education, advancing patient care and facilitating research.

http://www.clfoundation.org

Last Updated: 6 Jan 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Mycosis fungoides" returned 386 free, full-text research articles on human participants. First 3 results:

Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides.
 

Author(s): Gustavo Moreira Amorim, João Paulo Niemeyer Corbellini, Danielle Carvalho Quintella, Tullia Cuzzi, Márcia Ramos-E-Silva

Journal: An Bras Dermatol. ;93(5):680-685.

 

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma. TNMB system is the staging method used in MF, and it not only guides therapeutic management, but represents the main prognostic factor. In order to improve the prognostic evaluation, the Cutaneous Lymphoma ...

Last Updated: 31 Dec 1969

Go To URL
Clinical and epidemiological profile of patients with early stage mycosis fungoides.
 

Author(s): Gustavo Moreira Amorim, João Paulo Niemeyer-Corbellini, Danielle Carvalho Quintella, Tullia Cuzzi, Márcia Ramos-E-Silva

Journal: An Bras Dermatol. ;93(4):546-552.

 

Mycosis fungoides is the most common form of primary cutaneous lymphoma, with an indolent, slowly progressive course and 88% five-year survival rate. The diagnosis is challenging, especially in the early stages, and usually relies on a good clinical-histopathological correlation.

Last Updated: 31 Dec 1969

Go To URL
Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
 

Author(s): Zhengbang Dong, Xiaomei Zhu, Yang Li, Lu Gan, Hao Chen, Wei Zhang, Jianfang Sun

Journal: Medicine (Baltimore). 2018 May;97(21):e10871.

 

Patients with mycosis fungoides (MF) developing tumors or extracutaneous lesions usually have a poor prognosis with no cure has so far been available. To identify potential novel biomarkers for MF at the tumor stage, a genomic mapping of 41 cutaneous lymphoma biopsies was used to ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Mycosis fungoides" returned 42 free, full-text review articles on human participants. First 3 results:

Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
 

Author(s): Kendall Liner, Celeste Brown, Laura Y McGirt

Journal:

 

Nitrogen mustard is a chemotherapeutic agent that has a well-documented safety and efficacy profile in the treatment of cutaneous T-cell lymphoma. Development of nitrogen mustard formulations and treatment regimens has been studied extensively over the last 40 years. In the last 5 ...

Last Updated: 31 Dec 1969

Go To URL
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
 

Author(s): Franz Trautinger, Johanna Eder, Chalid Assaf, Martine Bagot, Antonio Cozzio, Reinhard Dummer, Robert Gniadecki, Claus-Detlev Klemke, Pablo L Ortiz-Romero, Evangelia Papadavid, Nicola Pimpinelli, Pietro Quaglino, Annamari Ranki, Julia Scarisbrick, Rudolf Stadler, Liisa Väkevä, Maarten H Vermeer, Sean Whittaker, Rein Willemze, Robert Knobler

Journal: Eur. J. Cancer. 2017 05;77():57-74.

 

In order to provide a common standard for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), the European Organisation for Research and Treatment of Cancer-Cutaneous Lymphoma Task Force (EORTC-CLTF) published in 2006 its consensus recommendations for the stage-adapted ...

Last Updated: 31 Dec 1969

Go To URL
The biomarker landscape in mycosis fungoides and Sézary syndrome.
 

Author(s): Brittany Dulmage, Larisa Geskin, Joan Guitart, Oleg E Akilov

Journal: Exp. Dermatol.. 2017 08;26(8):668-676.

 

The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
 

Status: Not yet recruiting

Condition Summary: Mycosis Fungoides

 

Last Updated: 21 Oct 2016

Go to URL
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
 

Status: Recruiting

Condition Summary: Refractory Mycosis Fungoides

 

Last Updated: 16 Nov 2017

Go to URL
Dosing of Brentuximab Vedotin for Mycosis Fungoides Patients
 

Status: Recruiting

Condition Summary: Mycosis Fungoides; Lymphomatoid Papulosis

 

Last Updated: 3 Jul 2018

Go to URL